MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...
AtriCure, Inc. ATRC recently announced receipt of regulatory approval from China’s National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System. This ...
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (ATRC) (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, ...
MASON, Ohio, December 17, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) ...
Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback